Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1328-1331
10.1182/blood-2022-157829